CLC Bio and Dotmatics both announced this week that they have signed agreements with distributors for the Japanese market.
CLC Bio, based in Aarhus, Denmark, said that Filgen, a Nagoya, Japan-based provider of bioscience and nanoscience products, will resell its software for next-generation sequence analysis.
In addition, the firm has appointed David Leangen as CEO of CLC Bio Japan (see people in the news, this issue).
Michael Heltzen, director of partner sales at CLC Bio, said in a statement that the company has seen "a considerable increase of interest" this year from Japan for its next-generation sequencing software.
Dotmatics, meantime, a cheminformatics firm based in Bishop's Stortford, UK, has partnered with Tokyo-based Infocom.
As part of the agreement, Dotmatics and Infocom are working together to provide "dynamic query and visualization solutions" for pharmaceutical companies in Japan, Dotmatics said.